Trial Profile
Phase 2 Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Nov 2023
Price :
$35
*
At a glance
- Drugs Olaparib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 20 Nov 2023 Status changed from active, no longer recruiting to completed.
- 09 May 2023 Planned primary completion date changed from 1 Apr 2023 to 1 Jun 2023.
- 18 Apr 2023 Planned primary completion date changed from 1 Mar 2023 to 1 Apr 2023.